MSH|^~\&|LAB|LMH|||201911071142||ORU^R01|4101683|D|2.3|||AL|NE
PID|1||LM00005042|LM4926|LABLISTEST^LMWAM^PT1||19700201|F||||||||||LM000532/18|
OBR|1|32076^LAB|00024715^2708:HC00006R^LAB^270819:HC6^32076|231.2500^PF4^Anti-Platelet Factor 4 Group^^^34701-3||201908271154|201908271154|||||||201908271154||||||||||LAB|I||||
OBX|1|ST|231.2485^HIT R^Platelet PF4 Antibodies^^45155-9^|1|1.1^^Y|U/mL|<1.0|H||A^S|C|||201911071142
NTE|1||This assay has a sensitivity of at least 95% and a
NTE|2||specificity of 75% at the 1.0 U/mL cut-off.  For results
NTE|3||>4.0 U/mL the specificity is 95%. HIT remains a clinical
NTE|4||diagnosis and results should be interpreted using the 4T's
NTE|5||probability score.
NTE|6||* CRITICAL VALUE
NTE|7||
NTE|8||   ****   CORRECTED RESULT  ****
NTE|9||   ---  07/11/19 1141 ---
NTE|10||  Anti-PF4 previously reported as: 1.1  H U/mL
NTE|11||This assay has a sensitivity of at least 95% and a
NTE|12||specificity of 75% at the 1.0 U/mL cut-off.  For results
NTE|13||>4.0 U/mL the specificity is 95%. HIT remains a clinical
NTE|14||diagnosis and results should be interpreted using the 4T's
NTE|15||probability score.
NTE|16||
NTE|17||This assay has a sensitivity of at least 95% and a
NTE|18||specificity of 75% at the 1.0 U/mL cut-off.  For results
NTE|19||>4.0 U/mL the specificity is 95%. HIT remains a clinical
NTE|20||diagnosis and results should be interpreted using the 4T's
NTE|21||probability score.